These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 23509156)
1. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Reiners KS; Topolar D; Henke A; Simhadri VR; Kessler J; Sauer M; Bessler M; Hansen HP; Tawadros S; Herling M; Krönke M; Hallek M; Pogge von Strandmann E Blood; 2013 May; 121(18):3658-65. PubMed ID: 23509156 [TBL] [Abstract][Full Text] [Related]
2. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles. Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836 [TBL] [Abstract][Full Text] [Related]
3. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. Sportoletti P; De Falco F; Del Papa B; Baldoni S; Guarente V; Marra A; Dorillo E; Rompietti C; Adamo FM; Ruggeri L; Di Ianni M; Rosati E Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206399 [TBL] [Abstract][Full Text] [Related]
4. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C Front Immunol; 2021; 12():619069. PubMed ID: 34108958 [TBL] [Abstract][Full Text] [Related]
6. A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells. Binici J; Hartmann J; Herrmann J; Schreiber C; Beyer S; Güler G; Vogel V; Tumulka F; Abele R; Mäntele W; Koch J J Biol Chem; 2013 Nov; 288(48):34295-303. PubMed ID: 24133212 [TBL] [Abstract][Full Text] [Related]
7. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Parry HM; Stevens T; Oldreive C; Zadran B; McSkeane T; Rudzki Z; Paneesha S; Chadwick C; Stankovic T; Pratt G; Zuo J; Moss P Oncotarget; 2016 Oct; 7(42):68513-68526. PubMed ID: 27655680 [TBL] [Abstract][Full Text] [Related]
8. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896 [TBL] [Abstract][Full Text] [Related]
9. PILRα binds an unknown receptor expressed primarily on CD56bright and decidual-NK cells and activates NK cell functions. Ophir Y; Duev-Cohen A; Yamin R; Tsukerman P; Bauman Y; Gamliel M; Mandelboim O Oncotarget; 2016 Jul; 7(27):40953-40964. PubMed ID: 27029068 [TBL] [Abstract][Full Text] [Related]
10. Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo. Gong W; Xiao W; Qian L; Gong C; Hu M; Pan X; Ji M Cell Mol Immunol; 2010 Nov; 7(6):477-84. PubMed ID: 20871627 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218 [TBL] [Abstract][Full Text] [Related]
12. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031 [TBL] [Abstract][Full Text] [Related]
13. Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Hadadi L; Hafezi M; Amirzargar AA; Sharifian RA; Abediankenari S; Asgarian-Omran H Oncol Res Treat; 2019; 42(4):202-208. PubMed ID: 30870839 [TBL] [Abstract][Full Text] [Related]